Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749112 | 0.99 | KIT (0.36) | KITKDREPHA2EPHB4FLT1 | |
| SCHEMBL1748733 | 0.87 | HRH3 (0.40) | KITKDREPHA2EPHB4EGFR | |
| SCHEMBL1749060 | 0.86 | PTGDR2 (0.37) | KITKDREPHA2EPHB4FLT1 | |
| SCHEMBL1748775 | 0.86 | PTGDR2 (0.37) | KDREPHA2EPHB4MET | |
| SCHEMBL1748718 | 0.85 | PTGDR2 (0.39) | KDREPHA2EPHB4MET | |
| SCHEMBL1749146 | 0.85 | PTGDR2 (0.36) | KDREPHA2EPHB4MET | |
| SCHEMBL1749273 | 0.81 | PTGDR2 (0.39) | — | |
| SCHEMBL1748734 | 0.81 | EPHA2 (0.33) | KDREPHA2EPHB4 | |
| SCHEMBL1748689 | 0.79 | TP53 (0.39) | GAA | |
| SCHEMBL1748698 | 0.79 | TP53 (0.39) | KITKDREPHA2EPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | KIT 478/4885KDR 513/4885EPHA2 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.